⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RARE News
Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
globenewswire.com
RARE
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
globenewswire.com
RARE
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
globenewswire.com
RARE
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
globenewswire.com
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
RARE
Ultragenyx annuncia l'approvazione da parte dell'AIFA (Agenzia Italiana del Farmaco) del rimborso di Evkeeza® (evinacumab) per i pazienti pediatrici di età pari a 6 mesi con ipercolesterolemia familiare omozigote (HoFH)
globenewswire.com
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
RARE
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
globenewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
prnewswire.com
RARE